Selective FLT3 inhibition of FLT3-ITD+ acute myeloid leukaemia resulting in secondary D835Y mutation: A model for emerging clinical resistance patterns

Leukemia

Volumn 26, Issue 7, 2012, Pages 1462-1470

  Moore, A S ^a,b   Faisal, A ^a   De Castro, D Gonzalez ^a   Bavetsias, V ^a   Sun, C ^a   Atrash, B ^a   Valenti, M ^a   De Haven Brandon, A ^a   Avery, S ^a   Mair, D ^a   Mirabella, F ^a   Swansbury, J ^a   Pearson, A D J ^a,b   Workman, P ^a   Blagg, J ^a   Raynaud, F I ^a   Eccles, S A ^a   Linardopoulos, S ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

AML; aurora; FLT3; inhibitor; kinase; resistance

Indexed keywords

AURORA KINASE INHIBITOR; CCT 137690; FLT3 LIGAND; QUIZARTINIB; SORAFENIB; TANDUTINIB; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ALLELE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL LINE; CONTROLLED STUDY; DRUG BLOOD LEVEL; GENE DUPLICATION; GENE MUTATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO CULTURE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; XENOGRAFT;

ANIMALS; APOPTOSIS; BENZENESULFONATES; BENZOTHIAZOLES; BLOTTING, WESTERN; CELL CYCLE; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; FEMALE; FMS-LIKE TYROSINE KINASE 3; HUMANS; IMIDAZOLES; LEUKEMIA, MYELOID, ACUTE; MICE; MICE, NUDE; MUTATION; PHENYLUREA COMPOUNDS; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; PYRIDINES; QUINAZOLINES; TANDEM REPEAT SEQUENCES; TUMOR CELLS, CULTURED;

EID: 84863785488     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2012.52     Document Type: Article

References (41)

1. Smith ML, Hills RK, Grimwade D. Independent prognostic variables in acute myeloid leukaemia. Blood Rev 2010; 25: 39-51.
2. Meshinchi S, Appelbaum FR. Structural and functional alterations of FLT3 in acute myeloid leukemia. Clin Cancer Res 2009; 15: 4263-4269.
3. Whitman SP, Archer KJ, Feng L, Baldus C, Becknell B, Carlson BD et al. Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study. Cancer Res 2001; 61: 7233-7239.
4. Meshinchi S, Alonzo TA, Stirewalt DL, Zwaan M, Zimmerman M, Reinhardt D et al. Clinical implications of FLT3 mutations in pediatric AML. Blood 2006; 108: 3654-3661.
5. Mead AJ, Linch DC, Hills RK, Wheatley K, Burnett AK, Gale RE. FLT3 tyrosine kinase domain mutations are biologically distinct from and have a significantly more favorable prognosis than FLT3 internal tandem duplications in patients with acute myeloid leukemia. Blood 2007; 110: 1262-1270.
6. Whitman SP, Ruppert AS, Radmacher MD, Mrozek K, Paschka P, Langer C et al. FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications. Blood 2008; 111: 1552-1559.
7. Knapper S. The clinical development of FLT3 inhibitors in acute myeloid leukemia. Expert Opin Investig Drugs 2011; 20: 1377-1395.
8. Levis MJ. Will newer tyrosine kinase inhibitors have an impact in AML? Best Pract Res Clin Haematol 2010; 23: 489-494.
9. Smith CC, Chin J, Wang Q, Salerno S, Damon LE, Hunt JP et al. Validation of FLT3-ITD as a therapeutic target in human acute myeloid leukemia. Blood (ASH Annual Meeting Abstracts) 2011; 118 (abstract 937).
10. Carmena M, Earnshaw WC. The cellular geography of aurora kinases. Nat Rev Mol Cell Biol 2003; 4: 842-854.
11. Moore AS, Blagg J, Linardopoulos S, Pearson AD. Aurora kinase inhibitors: novel small molecules with promising activity in acute myeloid and Philadelphiapositive leukemias. Leukemia 2010; 24: 671-678.
12. Girdler F, Gascoigne KE, Eyers PA, Hartmuth S, Crafter C, Foote KM et al. Validating Aurora B as an anti-cancer drug target. J Cell Sci 2006; 119: 3664-3675.
13. Carpinelli P, Moll J. Aurora kinase inhibitors: identification and preclinical validation of their biomarkers. Expert Opin Ther Targets 2008; 12: 69-80.
14. Vader G, Medema RH, Lens SM. The chromosomal passenger complex: guiding Aurora-B through mitosis. J Cell Biol 2006; 173: 833-837.
15. Lowenberg B, Muus P, Ossenkoppele G, Rousselot P, Cahn JY, Ifrah N et al. Phase I/II study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemia. Blood 2011; 118: 6030-6036.
16. Goldberg SL, Fenaux P, Craig MD, Gyan E, Lister J, Kassis J et al. Phase 2 study of MLN8237, an investigational Aurora A kinase (AAK) inhibitor in patients with acute myelogenous leukemia (AML) or myelodysplastic syndromes (MDS). Blood (ASH Annual Meeting Abstracts) 2010; 116 (abstract 3273).
17. Bavetsias V, Large JM, Sun C, Bouloc N, Kosmopoulou M, Matteucci M et al. Imidazopyridine derivatives as inhibitors of Aurora kinases: lead optimization studies toward the identification of an orally bioavailable preclinical development candidate. J Med Chem 2010; 53: 5213-5228.
18. Bavetsias V, Sun C, Bouloc N, Reynisson J, Workman P, Linardopoulos S et al. Hit generation and exploration: imidazopyridine derivatives as inhibitors of Aurora kinases. Bioorg Med Chem Lett 2007; 17: 6567-6571.
19. Chan F, Sun C, Perumal M, Nguyen QD, Bavetsias V, McDonald E et al. Mechanism of action of the Aurora kinase inhibitor CCT129202 and in vivo quantification of biological activity. Mol Cancer Ther 2007; 6: 3147-3157.
20. Drexler HG. Guide to Leukemia-Lymphoma Cell Lines, 2nd edn. Braunschweig, 2010.
21. Murphy KM, Levis M, Hafez MJ, Geiger T, Cooper LC, Smith BD et al. Detection of FLT3 internal tandem duplication and D835 mutations by a multiplex polymerase chain reaction and capillary electrophoresis assay. J Mol Diagn 2003; 5: 96-102.
22. Workman P, Aboagye EO, Balkwill F, Balmain A, Bruder G, Chaplin DJ et al. Guidelines for the welfare and use of animals in cancer research. Br J Cancer 2010; 102: 1555-1577.
23. Smith CC, Damon L, Salerno S, Shah NP. Saturation mutagenesis of FLT3-ITD: AC220-resistance-conferring kinase domain mutations are restricted to a limited number of residues and are cross-resistant to sorafenib in vitro. Am Assoc Cancer Res (AACR) Meeting Abstracts 2011 (abstract 4737).
24. Quentmeier H, Reinhardt J, Zaborski M, Drexler HG. FLT3 mutations in acute myeloid leukemia cell lines. Leukemia 2003; 17: 120-124.
25. Rosnet O, Stephenson D, Mattei MG, Marchetto S, Shibuya M, Chapman VM et al. Close physical linkage of the FLT1 and FLT3 genes on chromosome 13 in man and chromosome 5 in mouse. Oncogene 1993; 8: 173-179.
26. Kiyoi H, Shiotsu Y, Ozeki K, Yamaji S, Kosugi H, Umehara H et al. A novel FLT3 inhibitor FI-700 selectively suppresses the growth of leukemia cells with FLT3 mutations. Clin Cancer Res 2007; 13: 4575-4582.
27. Mizuki M, Fenski R, Halfter H, Matsumura I, Schmidt R, Müller C et al. Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways. Blood 2000; 96: 3907-3914.
28. Zarrinkar PP, Gunawardane RN, Cramer MD, Gardner MF, Brigham D, Belli B et al. AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML). Blood 2009; 114: 2984-2992.
29. Clark JJ, Cools J, Curley DP, Yu JC, Lokker NA, Giese NA et al. Variable sensitivity of FLT3 activation loop mutations to the small molecule tyrosine kinase inhibitor MLN518. Blood 2004; 104: 2867-2872.
30. von Bubnoff N, Engh RA, Aberg E, Sanger J, Peschel C, Duyster J. FMS-like tyrosine kinase 3-internal tandem duplication tyrosine kinase inhibitors display a nonoverlapping profile of resistance mutations in vitro. Cancer Res 2009; 69: 3032-3041.
31. Smith CC, Damon LE, Zhu X, Salerno S, Shah N. Analysis of in vitro activity of the clinically-active ABL/FLT3 inhibitor Ponatinib (AP24534) against AC220-resistant FLT3-ITD mutants. Blood (ASH Annual Meeting Abstracts) 2011; 118 (abstract 930).
32. Smith CC, Perl AE, Lasater E, Zhang C, Jeschke GR, Damon LE et al. PLX3397 is an investigational selective FLT3 inhibitor that retains activity against the clinicallyrelevant FLT3-ITD/F691 L 'gatekeeper' mutation in vitro. Blood (ASH Annual Meeting Abstracts) 2011; 118 (abstract 764).
33. Fiskus W, Smith CC, Smith J, Wise SC, Lasater E, Damon LE et al. Activity of allosteric, switch-pocket, ABL/FLT3 kinase inhibitor DCC2036 against cultured and primary aml progenitors with FLT-ITD or FLT3 kinase domain mutations. Blood (ASH Annual Meeting Abstracts) 2011; 118 (abstract 2611).
34. Heidel F, Solem FK, Breitenbuecher F, Lipka DB, Kasper S, Thiede MH et al. Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain. Blood 2006; 107: 293-300.
35. Shih LY, Huang CF, Wu JH, Lin TL, Dunn P, Wang PN et al. Internal tandem duplication of FLT3 in relapsed acute myeloid leukemia: a comparative analysis of bone marrow samples from 108 adult patients at diagnosis and relapse. Blood 2002; 100: 2387-2392.
36. Pratz KW, Sato T, Murphy KM, Stine A, Rajkhowa T, Levis M. FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML. Blood 2010; 115: 1425-1432.
37. Raghavan M, Smith LL, Lillington DM, Chaplin T, Kakkas I, Molloy G et al. Segmental uniparental disomy is a commonly acquired genetic event in relapsed acute myeloid leukemia. Blood 2008; 112: 814-821.
38. Li L, Bailey E, Greenblatt S, Huso D, Small D. Loss of the wild-type allele contributes to myeloid expansion and disease aggressiveness in FLT3/ITD knockin mice. Blood 2011; 118: 4935-4945.
39. Thiede C, Steudel C, Mohr B, Schaich M, Schakel U, Platzbecker U et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood 2002; 99: 4326-4335.
40. Chen W, Jones D, Medeiros LJ, Luthra R, Lin P. Acute myeloid leukaemia with FLT3 gene mutations of both internal tandem duplication and point mutation type. Br J Haematol 2005; 130: 726-728.
41. Carnicer MJ, Nomdedeu JF, Lasa A, Estivill C, Brunet S, Aventin A et al. FLT3 mutations are associated with other molecular lesions in AML. Leuk Res 2004; 28: 19-23.